IgA nephropathy (IgAN, sometimes called Berger's disease) is a chronic kidney disease where abnormal IgA antibodies form immune complexes that deposit in the glomeruli, trigger complement-mediated inflammation, and damage the filtering units of the kidney over time. Approximately 130,000-150,000 Americans have primary IgAN, and roughly 30-40% of adult patients progress to end-stage kidney disease within 20-25 years of diagnosis without effective treatment. IgAN is the most common primary glomerular disease worldwide.
The 2026 IgAN treatment landscape expanded rapidly. Standard of care per the February 2026 KDIGO clinical practice guidelines remains ACE inhibitors or ARBs plus SGLT2 inhibitors (Farxiga/dapagliflozin) plus, for patients with persistent proteinuria, endothelin receptor blockers (Filspari/sparsentan or Vanrafia/atrasentan). Add-on mechanism-targeted therapy accelerated across ten days in July: Vera Therapeutics' TRUTAKNA (atacicept-vymj), a BAFF/APRIL-blocking peptide-and-Fc fusion protein, received FDA accelerated approval on July 7 (Phase 3 ORIGIN: 45.7% UPCR reduction at 36 weeks). Novartis Fabhalta (iptacopan), a complement Factor B small molecule, received FDA traditional approval on July 17 (Phase 3 APPLAUSE-IgAN: 48% slower eGFR decline versus placebo). Vertex Pharmaceuticals' povetacicept (another BAFF/APRIL fusion) has a PDUFA target action date of November 30, 2026 (Phase 3 topline: 49.8% UPCR reduction). Otsuka's Voyxact (sibeprenlimab, anti-APRIL antibody) received earlier 2026 FDA accelerated approval.
On September 23, 2026, Roche reported that sefaxersen, an antisense drug licensed from Ionis, met the 37-week proteinuria endpoint in a prespecified interim analysis of the 459-patient Phase 3 IMAgINATION trial. Roche did not disclose the size of the reduction, and the trial continues blinded to week 105 to measure eGFR. Sefaxersen is a monthly subcutaneous injection that lowers liver production of complement factor B, the same protein Fabhalta inhibits with a pill.
Stories here cover IgAN clinical trial readouts, FDA approvals, competitive positioning across mechanisms (BAFF/APRIL, complement, endothelin), and payer coverage of the new peptide-and-biologic entries. See #trutakna, #fabhalta, and #vera-therapeutics for adjacent threads.
Roche said on September 23, 2026 that a prespecified interim analysis of the Phase 3 IMAgINATION trial found sefaxersen produced a statistically significant reduction in 24-hour urine protein-to-creatinine ratio versus placebo at 37 weeks in adults with primary IgA nephropathy at high risk of progression. The trial randomized 459 people 1:1 to sefaxersen, a once-monthly subcutaneous antisense drug that reduces liver production of complement factor B, or to placebo for 105 weeks. Roche did not disclose the size of the proteinuria reduction; the trial remains blinded to week 105 to measure change in eGFR, and safety was consistent with prior data. Roche licensed sefaxersen from Ionis.
Vera Therapeutics reported on Tuesday, September 15, 2026 final efficacy results from the Phase 3 ORIGIN 3 trial of TRUTAKNA (atacicept-vymj) in 428 adults with primary IgA nephropathy at risk of progression. At 52 weeks, mean eGFR changed by -0.1 mL/min/1.73m² on TRUTAKNA versus -5.7 on placebo, and the annualized eGFR slope through 104 weeks was -0.6 versus -5.6 mL/min/1.73m² per year. TRUTAKNA cut the risk of composite kidney disease progression by 76% (hazard ratio 0.24; 11 versus 38 events), with no dialysis, transplant, or death events versus 8 on placebo, and proteinuria, galactose-deficient IgA1, and hematuria also fell significantly. Safety was generally comparable to placebo. Vera plans to submit a supplemental BLA for full approval in the fourth quarter of 2026 and reported more than 350 patient start forms in the first ten weeks of launch.
TJ Biopharma and Biogen said China's National Medical Products Administration approved felzartamab for injection, branded Jingfei, on Thursday, August 13, 2026 for use with lenalidomide and dexamethasone in adults with multiple myeloma who have received at least one prior line of therapy. It is the anti-CD38 antibody's first approval anywhere; TJ Biopharma submitted the application in December 2024. In April 2026 Biogen agreed to pay $100 million upfront and up to $750 million in milestones for TJ Biopharma's Greater China rights, giving Biogen worldwide rights; Biogen handles commercialization in the region, and TJ Biopharma manufactures the drug at its Hangzhou facility. Outside China, Biogen is testing felzartamab in Phase 3 trials in antibody-mediated rejection after kidney transplant, IgA nephropathy, and primary membranous nephropathy.
Boulevard Bio emerged from stealth on Wednesday August 12, 2026 with $65 million in founding financing from Deerfield Management, naming Georg Schett (one of the pioneers of immune reset in autoimmune disease) as co-founder. The company disclosed a precision-immunology pipeline of three drug candidates anchored by BLVD101, an internally discovered dual BAFF/APRIL-targeting bispecific antibody. Mechanism: BLVD101 is designed to inhibit BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand), two cytokines that promote the proliferation, survival, and maturation of B cells that drive autoimmune disorders. By blocking both cytokines simultaneously, BLVD101 aims to limit the abnormal B cell activity that attacks healthy tissue in autoimmune diseases. Early Phase 1 healthy volunteer data supports a 12-week (quarterly) subcutaneous dosing interval for BLVD101 in IgA nephropathy (IgAN), a positive tolerability and pharmacokinetic profile that would compare favorably against monthly-dosing biologics in adjacent indications. The launch extends the IgAN indication activity that Trutakna and Fabhalta opened up earlier in 2026 with their FDA approvals ten days apart in the same indication category, though those two drugs target the complement pathway (factor B, C5) rather than the B-cell BAFF/APRIL axis that BLVD101 addresses.
Vera Therapeutics (NASDAQ: VERA) confirmed commercial-launch parameters for TRUTAKNA (atacicept-vymj) following the July 7, 2026 FDA accelerated approval for adults with primary IgA nephropathy at risk of rapid disease progression. List price: $425,000 per year for the recombinant peptide-and-Fc fusion protein (TACI extracellular domain fused to human IgG1 Fc). Sales force: 82 representatives deployed at launch. Distribution: in-channel pharmacy availability within three to four weeks of approval, with insurance coverage under specialty-pharmacy medical benefit pathways given the subcutaneous injection administration. The July 7 accelerated approval was based on the Phase 3 ORIGIN study 36-week urine protein-to-creatinine ratio (UPCR) endpoint (45.7% reduction versus 6.8% for standard of care). Continued FDA approval may be contingent on verification of clinical benefit in the ongoing ORIGIN 3 confirmatory trial, which continues in a placebo-controlled blinded manner to evaluate change in kidney function as measured by estimated glomerular filtration rate (eGFR); results are anticipated in Q3 2026. If the ORIGIN 3 eGFR data hit, TRUTAKNA converts to traditional approval on the harder outcome endpoint.
Vertex Pharmaceuticals' (NASDAQ: VRTX) povetacicept, a BAFF/APRIL-blocking fusion protein for primary IgA nephropathy, has US FDA acceptance of its Biologics License Application with a PDUFA target action date of November 30, 2026. Povetacicept works through the same mechanism as Vera Therapeutics' TRUTAKNA (atacicept-vymj), targeting the BAFF and APRIL cytokines that drive plasma-cell antibody production. Phase 3 topline data reported in March 2026 showed a 49.8% reduction in urine protein-creatinine ratio (UPCR) at 36 weeks in povetacicept-treated patients versus placebo (versus 45.7% for TRUTAKNA in the ORIGIN Phase 3). BioSpace analysis published this weekend characterizes the Vertex program as derisked following the Vera TRUTAKNA approval on July 7 and the Novartis Fabhalta traditional approval on July 17 — both marketing campaigns will build IgAN awareness and educate nephrologists on the treatment landscape before povetacicept reaches market, and both approvals validate the FDA's willingness to green-light novel IgAN mechanisms on accelerated pathways. Povetacicept, if approved, would become the first commercialized therapy in Vertex's emerging nephrology franchise.
Novartis (SIX: NOVN) announced Friday July 17, 2026 that the FDA has granted traditional approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. Fabhalta is a first-in-class complement Factor B inhibitor (small molecule); the traditional approval converts the August 2024 FDA accelerated approval (which was based on proteinuria reduction) into a full label supported by kidney-function outcomes. The Phase 3 APPLAUSE-IgAN trial showed a 3.02 mL/min/1.73 m² per year difference in estimated glomerular filtration rate (eGFR) slope in the iptacopan arm versus placebo, translating to a 48% slower kidney-function decline. The approval extends the primary IgA nephropathy competitive set that Vera Therapeutics entered on July 7, 2026 when Trutakna (atacicept-vymj), a BAFF/APRIL-targeting peptide-and-Fc fusion protein, received FDA accelerated approval based on a 45.7% versus 6.8% reduction in urine protein-to-creatinine ratio in the Phase 3 ORIGIN trial. IgA nephropathy affects approximately 130,000-150,000 Americans and is the most common primary glomerular disease worldwide; roughly 40% of patients progress to end-stage renal disease within 20 years without effective treatment.
The FDA granted accelerated approval Tuesday July 7, 2026 to Trutakna (atacicept-vymj) for adult patients with primary IgA nephropathy (IgAN) at risk of rapid disease progression, in combination with standard of care. Vera Therapeutics developed the drug as a recombinant fusion protein that combines the extracellular domain of the transmembrane activator and CAML interactor (TACI) receptor with the Fc portion of human IgG1, binding both B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) to reduce autoantibody-driven kidney damage. The registrational Phase 3 ORIGIN trial data supporting approval: at 36 weeks, Trutakna plus standard of care produced a 45.7% reduction in urine protein-to-creatinine ratio versus a 6.8% reduction for standard of care alone. IgA nephropathy affects approximately 130,000 to 150,000 Americans and is the most common primary glomerular disease worldwide; approximately 40% of patients progress to end-stage renal disease within 20 years without adequate treatment. Trutakna is a fusion protein rather than a peptide but sits in adjacent therapeutic territory relevant to the site's peptide-and-biologic coverage. Vera Therapeutics (NASDAQ: VERA) is expected to launch the product in Q3 2026. Continued approval may be contingent on verification of clinical benefit in confirmatory Phase 3 studies.